Nimotuzumab is named as a drug or biological intervention in 24 clinical trials in our China trial register, 15 of which are recruiting. Lead sponsors include Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4), Zhejiang University (3) and Fudan University (3). Registered phases: Phase 2, Phase 3, Phase 1/2, Phase 2/3 and Not applicable. Conditions studied include Head & Neck Cancer; Nasopharyngeal Carcinoma; Pancreatic Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Head & Neck Cancer | 5 |
| Nasopharyngeal Carcinoma | 4 |
| Pancreatic Cancer | 2 |
| Head and Neck Squamous Cell Carcinoma | 2 |
| Nasopharyngeal Carcinoma by AJCC V8 Stage | 2 |
| Esophageal Cancer | 2 |
| Head & Neck Squamous Cell Carcinoma | 2 |
| Chemoradiation | 2 |
| Metastatic Pancreatic Carcinoma | 1 |
| Uterine Cervical Neoplasms | 1 |
| Radiotherapy | 1 |
| Pancreatic Neuroendocrine Neoplasm | 1 |
| RAS Mutations or Amplifications | 1 |
| Head and Neck Squamous Cell Carcinoma (HNSCC) | 1 |
| Neoadjuvant Therapy | 1 |
| Borderline Resectable Pancreatic Adenocarcinoma | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Esophagus Cancer | 1 |
| Esophagogastric Junction Cancer | 1 |
| Targeted Therapy | 1 |
| Pancreatic Cancer, Adult | 1 |
| Postoperative Adjuvant Treatment | 1 |
| Resectable Esophageal Squamous Cell Carcinoma | 1 |
| Chemotherapy Effect | 1 |
| Surgery | 1 |
| Lead sponsor | Trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 4 |
| Zhejiang University | 3 |
| Fudan University | 3 |
| Sun Yat-sen University | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| Ke Hu | 1 |
| Tang-Du Hospital | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Fourth Affiliated Hospital of Guangxi Medical University | 1 |
| The First Affiliated Hospital of Zhengzhou University | 1 |
| Shandong Cancer Hospital and Institute | 1 |
| Peking University | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 1 |
| Register | Nimotuzumab trials |
|---|---|
| Clinical trials in China | 24 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Nimotuzumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nimotuzumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.